Thomas Jefferson University Hospitals INC

Thomas Jefferson University Hospitals INC was paid $40.28M by Medicaid between Jan 2018 and Dec 2024, across 452 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.

33Billing provider infoTHOMAS JEFFERSON UNIVERSITY HOSPITALS INC
PHILADELPHIA, PA 19107

33aNPI1215916002assigned 01/11/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$40.28M

24GClaims670,173

24DCodes billed452

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Pennsylvania

Rank by total paid#5 of 154

Median peer was paid$2.82M

This provider vs. median14×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	3,644	$133K
2019	14,789	$480K
2020	111,348	$5.51M
2021	262,530	$17.85M
2022	84,720	$5.68M
2023	99,015	$6.19M
2024incomplete	94,127	$4.44M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	25%	49,035	45,925	$10.23M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	15%	28,709	26,363	$5.98M
G0378	Hospital observation service, per hour	9.4%	4,948	2,784	$3.77M
99282	Emergency department visit for the evaluation and management, low to moderate severity	4.7%	9,792	8,325	$1.88M
77067	Screening mammography, bilateral, including computer-aided detection	3.7%	9,811	9,692	$1.48M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	3.4%	10,453	10,013	$1.36M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	3.3%	8,093	7,322	$1.35M
95810	Polysomnography; sleep staging with 4 or more additional parameters	3.2%	2,632	2,609	$1.28M
J9271	Injection, pembrolizumab, 1 mg	2.8%	1,404	1,129	$1.12M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	1.7%	4,696	4,621	$693K
77386		1.7%	1,824	161	$686K
J2323	Injection, natalizumab, 1 mg	1.7%	836	813	$669K

440 more codes

96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	1.5%	4,347	$623K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1.3%	1,019	$542K
T1015	A visit at a community health center or clinic (one all-in rate)	1.2%	7,805	$468K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	1.0%	7,356	$415K
77063	Screening digital breast tomosynthesis, bilateral	<1%	9,809	$389K
J2350	Injection, ocrelizumab, 1 mg	<1%	255	$361K
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	<1%	722	$279K
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	464	$217K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	726	$198K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	4,365	$198K
96375	Therapeutic injection; each additional sequential IV push	<1%	8,156	$181K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	34,127	$178K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	404	$161K
74183		<1%	235	$138K
0002A		<1%	1,755	$134K
J9299	Injection, nivolumab, 1 mg	<1%	34	$121K
80048	Basic metabolic panel (calcium, ionized)	<1%	23,854	$110K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	170	$106K
99214	Doctor's office visit, returning patient (more involved)	<1%	5,191	$106K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	835	$103K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	<1%	81	$100K
96417		<1%	989	$95K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	9,916	$92K
0001A		<1%	1,933	$88K
77301		<1%	95	$88K
Q5113	Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg	<1%	37	$84K
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	1,054	$82K
76642		<1%	1,045	$80K
77066	Tomosynthesis, mammo	<1%	487	$79K
76830	Ultrasound, transvaginal	<1%	1,018	$78K
94729		<1%	1,619	$77K
70450	Computed tomography, head or brain; without contrast material	<1%	2,275	$75K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	<1%	33	$73K
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	156	$72K
80053	Comprehensive metabolic panel	<1%	8,767	$70K
76641		<1%	631	$70K
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	593	$69K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	5,406	$67K
77412		<1%	1,006	$64K
92557		<1%	1,335	$64K
77334		<1%	474	$62K
94726		<1%	1,424	$61K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	2,239	$57K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	2,032	$55K
77336		<1%	820	$53K
93970		<1%	566	$52K
88185		<1%	242	$52K
OP370		<1%	503	$52K
77065	Tomosynthesis, mammo	<1%	445	$50K
G0399	Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation	<1%	513	$47K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	6,554	$46K
J1756	Injection, iron sucrose, 1 mg	<1%	4,744	$46K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	889	$43K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	132	$43K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	1,158	$42K
96415		<1%	833	$42K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	401	$40K
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	772	$39K
85027		<1%	4,466	$39K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	804	$37K
93017		<1%	672	$37K
71046	Radiologic examination, chest; 2 views	<1%	3,682	$35K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	1,657	$34K
86832		<1%	225	$34K
77300		<1%	294	$32K
C1769	Guide wire	<1%	706	$32K
70544		<1%	126	$31K
OP710		<1%	820	$30K
A9270	Non-covered item or service	<1%	59,526	$30K
96367		<1%	1,075	$29K
86833		<1%	228	$28K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	4,290	$28K
59025	Fetal non-stress test	<1%	1,215	$28K
99213	Doctor's office visit, returning patient (routine)	<1%	2,574	$28K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	<1%	315	$27K
84443	Thyroid stimulating hormone (TSH)	<1%	1,830	$26K
97162		<1%	695	$26K
J0185	Injection, aprepitant, 1 mg	<1%	928	$26K
93351		<1%	25	$26K
J2785	Injection, regadenoson, 0.1 mg	<1%	489	$25K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	199	$25K
0004A		<1%	278	$25K
76770		<1%	360	$24K
92588		<1%	379	$24K
77295		<1%	61	$24K
A9585	Injection, gadobutrol, 0.1 ml	<1%	1,635	$23K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	128	$23K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	420	$22K
93971		<1%	295	$22K
76536		<1%	250	$22K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	1,754	$22K
20611		<1%	225	$22K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	5,396	$21K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,376	$21K
36561		<1%	13	$21K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,376	$20K
71250		<1%	263	$20K
86480		<1%	445	$20K
72125	Computed tomography, cervical spine; without contrast material	<1%	832	$20K
93880		<1%	198	$20K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	2,208	$19K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	429	$19K
86803		<1%	924	$19K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	318	$19K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	721	$19K
82784		<1%	670	$19K
80076		<1%	4,258	$18K
96402		<1%	385	$18K
99215	Doctor's office visit, returning patient (complex)	<1%	1,083	$18K
83735		<1%	5,390	$18K
80061	Lipid panel	<1%	1,399	$17K
J9070	Cyclophosphamide, 100 mg	<1%	127	$17K
88342		<1%	755	$17K
85730		<1%	3,955	$17K
92567		<1%	886	$17K
93975		<1%	243	$17K
86900		<1%	3,934	$16K
96411		<1%	185	$16K
36415	Collection of venous blood by venipuncture	<1%	10,658	$15K
96409		<1%	106	$15K
19083		<1%	24	$15K
G0433	Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening	<1%	1,258	$15K
88341		<1%	320	$14K
G0463	Hospital outpatient clinic visit for assessment and management of a patient	<1%	9,651	$14K
94060		<1%	778	$14K
84484		<1%	5,046	$14K
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	580	$13K
86780		<1%	1,042	$13K
86850		<1%	2,817	$13K
36430		<1%	446	$13K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	1,303	$12K
71045	Radiologic examination, chest; single view	<1%	3,234	$12K
76881		<1%	91	$12K
97161		<1%	342	$12K
76882		<1%	705	$12K
85610		<1%	5,001	$12K
96401		<1%	187	$11K
71275	Computed tomographic angiography, chest, with contrast material	<1%	114	$11K
76942		<1%	217	$11K
99204	Doctor's office visit, new patient (more involved)	<1%	521	$11K
J3490	Unclassified drugs	<1%	14,373	$10K
83615		<1%	1,856	$10K
87086	Culture, bacterial; quantitative colony count, urine	<1%	2,515	$10K
96361	Intravenous infusion, hydration; each additional hour	<1%	1,374	$10K
87340		<1%	702	$10K
77290		<1%	104	$9K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	346	$9K
70486		<1%	295	$9K
93922		<1%	239	$9K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,684	$9K
31231		<1%	345	$8K
0012A		<1%	109	$8K
84100		<1%	1,747	$8K
88184		<1%	246	$8K
86901		<1%	3,344	$8K
C1729	Catheter, drainage	<1%	206	$8K
J2704	Injection, propofol, 10 mg	<1%	8,400	$8K
87480		<1%	402	$7K
74178		<1%	24	$7K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	53	$7K
87660		<1%	401	$7K
86706		<1%	585	$7K
0003A		<1%	76	$7K
83880		<1%	751	$7K
94010		<1%	497	$7K
82570		<1%	959	$7K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	15	$6K
86704		<1%	416	$6K
99203	Doctor's office visit, new patient (routine)	<1%	231	$6K
72110		<1%	247	$6K
96368		<1%	446	$6K
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	80	$6K
82728		<1%	651	$6K
0011A		<1%	111	$6K
76801		<1%	189	$5K
87077		<1%	1,133	$5K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	152	$5K
83883		<1%	424	$5K
82247		<1%	669	$5K
0124A		<1%	53	$5K
43235		<1%	13	$5K
84550		<1%	954	$5K
90715		<1%	644	$5K
96376		<1%	1,235	$5K
97163		<1%	132	$5K
87536		<1%	58	$5K
84702		<1%	766	$4K
81001		<1%	3,219	$4K
80197		<1%	284	$4K
73030		<1%	437	$4K
87510		<1%	339	$4K
84165		<1%	415	$4K
84153		<1%	261	$4K
J9267	Injection, paclitaxel, 1 mg	<1%	1,436	$4K
73564		<1%	418	$4K
83690		<1%	2,305	$4K
82248		<1%	545	$4K
91010		<1%	26	$3K
72050		<1%	88	$3K
86787		<1%	165	$3K
93356		<1%	12	$3K
0031A		<1%	52	$3K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	31	$3K
73630		<1%	436	$3K
83540		<1%	563	$3K
82803		<1%	583	$3K
73562		<1%	153	$3K
72141		<1%	13	$3K
72131		<1%	121	$3K
97150	Therapeutic procedure(s), group (2 or more individuals)	<1%	411	$3K
OP258		<1%	3,205	$3K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	198	$3K
J9045	Injection, carboplatin, 50 mg	<1%	1,201	$3K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	178	$3K
87040		<1%	610	$3K
82607		<1%	335	$3K
73610		<1%	382	$3K
80320		<1%	718	$3K
J1453	Injection, fosaprepitant, 1 mg	<1%	577	$3K
73130		<1%	457	$3K
82043		<1%	449	$3K
99205	Prolong outpt/office vis	<1%	140	$3K
87186		<1%	641	$3K
83605		<1%	1,175	$3K
92550		<1%	99	$3K
OP272		<1%	326	$2K
99153	Mod sedat endo service >5yrs	<1%	294	$2K
61782		<1%	13	$2K
84156		<1%	488	$2K
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	565	$2K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	1,955	$2K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	124	$2K
0064A		<1%	27	$2K
82378		<1%	188	$2K
0054A		<1%	109	$2K
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	799	$2K
74220		<1%	64	$2K
86762		<1%	106	$2K
77001		<1%	48	$2K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	1,982	$2K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	406	$2K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	9,726	$2K
83550		<1%	532	$2K
J3489	Injection, zoledronic acid, 1 mg	<1%	141	$2K
76376		<1%	86	$2K
86709		<1%	131	$2K
96523		<1%	75	$2K
99152		<1%	268	$2K
82746		<1%	221	$2K
85379		<1%	540	$2K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	43	$2K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	708	$2K
73502		<1%	142	$2K
31575		<1%	63	$2K
70543		<1%	15	$2K
87081		<1%	288	$2K
84439		<1%	282	$1K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	94	$1K
94760		<1%	371	$1K
81003		<1%	1,152	$1K
86708		<1%	99	$1K
31579		<1%	166	$1K
94664		<1%	85	$1K
82550		<1%	565	$1K
72128		<1%	55	$1K
64615		<1%	43	$1K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	11,009	$1K
87522	Neg quan hep c or qual rna	<1%	47	$1K
87070		<1%	442	$1K
82565		<1%	758	$1K
87075		<1%	353	$1K
95816		<1%	56	$1K
90632		<1%	47	$1K
77417		<1%	73	$1K
90686		<1%	434	$1K
82024		<1%	58	$1K
0072A		<1%	13	$1K
0071A		<1%	12	$1K
87631		<1%	34	$1K
80069		<1%	284	$1K
86140		<1%	749	$1K
82150		<1%	236	$1K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	70	$1K
85652		<1%	662	$1K
81002		<1%	597	$1K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	8,553	$995.23
85046		<1%	313	$977.94
J1170	Injection, hydromorphone, up to 4 mg	<1%	3,127	$960.05
88314		<1%	112	$939.24
G0008	Administration of influenza virus vaccine	<1%	530	$890.08
87205		<1%	522	$869.30
78306		<1%	13	$860.54
74018		<1%	75	$836.51
73080		<1%	139	$820.32
86301		<1%	45	$800.19
86769		<1%	28	$783.30
83970		<1%	47	$769.68
76937		<1%	98	$768.62
J9263	Injection, oxaliplatin, 0.5 mg	<1%	57	$756.64
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	10,830	$753.92
92526		<1%	25	$743.36
OP270		<1%	92	$729.31
86923		<1%	206	$728.43
86038		<1%	46	$698.52
82947		<1%	385	$692.19
84075		<1%	359	$687.08
70480		<1%	14	$640.82
97166		<1%	28	$637.90
J0280	Injection, aminophyllin, up to 250 mg	<1%	353	$636.24
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	683	$628.20
76870		<1%	13	$596.01
88142		<1%	32	$592.95
88311		<1%	103	$584.69
73590		<1%	107	$583.96
84460		<1%	243	$579.37
80329		<1%	130	$578.47
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	5,537	$577.65
86334		<1%	41	$555.53
0052A		<1%	53	$535.40
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	341	$528.25
97602		<1%	19	$511.32
51798		<1%	116	$500.46
84155		<1%	376	$497.20
84295		<1%	263	$497.07
86765		<1%	46	$495.60
J0640	Injection, leucovorin calcium, per 50 mg	<1%	386	$488.10
82310		<1%	299	$474.36
72100		<1%	40	$456.26
82164		<1%	56	$440.95
82435		<1%	260	$424.33
86300		<1%	13	$396.32
88307		<1%	203	$383.49
84520		<1%	300	$370.71
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	5,604	$369.49
82040		<1%	392	$367.58
73110		<1%	87	$361.50
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	1,440	$359.63
J7060	5% dextrose/water (500 ml = 1 unit)	<1%	964	$347.74
82374		<1%	226	$334.21
80348		<1%	15	$332.33
J2270	Injection, morphine sulfate, up to 10 mg	<1%	1,339	$326.94
94618		<1%	14	$323.56
0051A		<1%	22	$321.64
86645		<1%	12	$311.89
J0690	Injection, cefazolin sodium, 500 mg	<1%	2,844	$293.36
86304		<1%	15	$292.87
83655		<1%	29	$290.00
J1815	Injection, insulin, per 5 units	<1%	1,864	$279.80
86644		<1%	12	$265.68
J0780	Injection, prochlorperazine, up to 10 mg	<1%	372	$258.92
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	4,860	$247.27
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	262	$240.37
82105		<1%	26	$237.17
72170		<1%	43	$225.12
86592		<1%	66	$217.70
90670		<1%	14	$216.13
86618		<1%	53	$210.30
0352U		<1%	12	$201.59
OP250		<1%	77	$201.20
J1650	Injection, enoxaparin sodium, 10 mg	<1%	1,927	$200.37
82010		<1%	171	$187.93
J7030	Infusion, normal saline solution , 1000 cc	<1%	81	$187.65
86703		<1%	14	$180.46
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	<1%	12	$179.98
90662		<1%	391	$169.95
85097		<1%	14	$144.61
71101		<1%	33	$139.01
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	972	$138.78
82977		<1%	18	$126.73
87184		<1%	26	$126.31
84145		<1%	27	$125.04
J1644	Injection, heparin sodium, per 1000 units	<1%	1,961	$122.34
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	2,055	$115.12
80051		<1%	61	$111.91
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	985	$102.29
88304		<1%	91	$100.40
J2060	Injection, lorazepam, 2 mg	<1%	841	$91.27
G0009	Administration of pneumococcal vaccine	<1%	34	$74.34
81025		<1%	30	$72.57
87102		<1%	33	$59.51
73090		<1%	30	$58.97
86430		<1%	16	$54.61
82945		<1%	15	$52.10
J3370	Injection, vancomycin hcl, 500 mg	<1%	220	$51.35
84157		<1%	17	$49.23
87206		<1%	42	$42.04
84132		<1%	18	$42.03
85018		<1%	12	$40.77
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	87	$35.34
J9190	Injection, fluorouracil, 500 mg	<1%	116	$33.25
J7999	Compounded drug, not otherwise classified	<1%	687	$33.06
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	1,405	$26.13
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	248	$20.15
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	294	$18.18
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	39	$17.53
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	393	$16.90
89051		<1%	18	$16.32
82962		<1%	17	$12.20
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	183	$10.47
J1630	Injection, haloperidol, up to 5 mg	<1%	31	$9.69
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	15	$6.30
J3480	Injection, potassium chloride, per 2 meq	<1%	187	$4.36
J1171	Injection, hydromorphone, 0.1 mg	<1%	167	$3.81
91300		<1%	237	$0.46
00000		0%	1,397	$0.00
J0131	Injection, acetaminophen, not otherwise specified,10 mg	0%	449	$0.00
J1790	Injection, droperidol, up to 5 mg	0%	279	$0.00
J1940	Injection, furosemide, up to 20 mg	0%	63	$0.00
Q5120	Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg	0%	83	$0.00
J2370	Injection, phenylephrine hcl, up to 1 ml	0%	188	$0.00
J0461	Injection, atropine sulfate, 0.01 mg	0%	45	$0.00
J1805	Injection, esmolol hydrochloride, 10 mg	0%	25	$0.00
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	0%	93	$0.00
J2470	Injection, pantoprazole sodium, 40 mg	0%	24	$0.00
88300		0%	44	$0.00
J9395	Injection, fulvestrant, 25 mg	0%	25	$0.00
90732		0%	12	$0.00
90677		0%	12	$0.00
J7297	Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg	0%	13	$0.00
J2004	Injection, lidocaine hcl with epinephrine, 1 mg	0%	55	$0.00
J9000	Injection, doxorubicin hydrochloride, 10 mg	0%	40	$0.00
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	0%	433	$0.00
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	0%	24	$0.00
J1596	Injection, glycopyrrolate, 0.1 mg	0%	391	$0.00
J0897	Injection, denosumab, 1 mg	0%	131	$0.00
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	0%	303	$0.00
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	0%	337	$0.00
J3032	Injection, eptinezumab-jjmr, 1 mg	0%	12	$0.00
86735		0%	46	$0.00
J2916	Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg	0%	329	$0.00
J9075	Injection, cyclophosphamide, not otherwise specified, 5 mg	0%	18	$0.00
J1750	Injection, iron dextran, 50 mg	0%	97	$0.00
C9113	Injection, pantoprazole sodium, per vial	0%	18	$0.00
90653		0%	20	$0.00
J2919	Injection, methylprednisolone sodium succinate, 5 mg	0%	305	$0.00
87899		0%	15	$0.00
J9206	Injection, irinotecan, 20 mg	0%	21	$0.00
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	0%	15	$0.00
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	0%	24	$0.00
J0689	Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg	0%	31	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLUBARSKY, NEIL (SENIOR VICE PRESIDENT FOR FINANCE)

Same official

Other billing entities under LUBARSKY, NEIL

Full network →

Provider	Location	Paid
Methodist Hospital	Philadelphia, PA	$10.65M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.